Open AccessCost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Author(s) -
Yingtao Lin,
Ying Chen,
Tianxiu Liu,
Fang Kuang,
Ping Huang
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s335515
Subject(s) - medicine , docetaxel , irinotecan , oncology , cost effectiveness , incremental cost effectiveness ratio , chemotherapy , quality adjusted life year , cancer , colorectal cancer , risk analysis (engineering)